Patents by Inventor Haihong Ni

Haihong Ni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER
    Publication number: 20250059176
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Application
    Filed: November 6, 2024
    Publication date: February 20, 2025
    Inventors: Xiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI
  • Substituted nicotinimide inhibitors of BTK for treating cancer
    Patent number: 12162873
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: October 27, 2023
    Date of Patent: December 10, 2024
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni
  • SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER
    Publication number: 20240101545
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Application
    Filed: October 27, 2023
    Publication date: March 28, 2024
    Inventors: Xiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI
  • Substituted nicotinimide inhibitors of BTK for treating cancer
    Patent number: 11840513
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: December 12, 2023
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni
  • SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER
    Publication number: 20220298153
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Application
    Filed: May 25, 2022
    Publication date: September 22, 2022
    Inventors: Xiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI, Mark MULVIHILL
  • Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
    Patent number: 11345695
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: May 31, 2022
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill
  • SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE
    Publication number: 20190276446
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Application
    Filed: May 23, 2019
    Publication date: September 12, 2019
    Inventors: Xiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI, Mark MULVIHILL
  • SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN
    Publication number: 20190225611
    Abstract: The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Application
    Filed: April 12, 2019
    Publication date: July 25, 2019
    Inventors: Lee BABISS, Matthew CLARK, Anthony D. KEEFE, Mark J. MULVIHILL, Haihong NI, Louis RENZETTI, Frank RUEBSAM, Ce WANG, Zhifeng XIE, Ying ZHANG
  • Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
    Patent number: 10301297
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 28, 2019
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill
  • Substituted spirocyclic inhibitors of autotaxin
    Patent number: 10233182
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 19, 2019
    Assignee: X-Rx, Inc.
    Inventors: Lee Babiss, Matthew Clark, Anthony D. Keefe, Mark J. Mulvihill, Haihong Ni, Louis Renzetti, Frank Ruebsam, Ce Wang, Zhifeng Xie, Ying Zhang
  • SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN
    Publication number: 20180282332
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Application
    Filed: February 14, 2018
    Publication date: October 4, 2018
    Inventors: Lee BABISS, Matthew CLARK, Anthony D. KEEFE, Mark J. MULVIHILL, Haihong NI, Louis RENZETTI, Frank RUEBSAM, Ce WANG, Zhifeng XIE, Ying ZHANG
  • SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE
    Publication number: 20180222897
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Xiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI, Mark MULVIHILL
  • Substituted spirocyclic inhibitors of autotaxin
    Patent number: 10011601
    Abstract: The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: July 3, 2018
    Assignee: X-Rx, Inc.
    Inventors: Lee Babiss, Matthew Clark, Anthony D. Keefe, Mark J. Mulvihill, Haihong Ni, Louis Renzetti, Frank Ruebsam, Ce Wang, Zhifeng Xie, Ying Zhang
  • Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
    Patent number: 9951056
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: April 24, 2018
    Assignee: BEIJING INNOCARE PHARMA TECH CO., LTD.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill
  • SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN
    Publication number: 20170166568
    Abstract: The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Application
    Filed: April 3, 2015
    Publication date: June 15, 2017
    Applicant: X-Rx, Inc.
    Inventors: Lee Babiss, Matthew Clark, Anthony D. Keefe, Mark J. Mulvihill, Haihong Ni, Louis Renzetti, Frank Ruebsam, Ce Wang, Zhifeng Xie, Ying Zhang
  • SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES
    Publication number: 20170037007
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 9, 2017
    Inventors: Frank Ruebsam, Ce Wang, Haihong Ni, Mark J. Mulvihill, Lee Babiss, Louis Renzetti, Ying Zhang
  • SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE
    Publication number: 20160237075
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Application
    Filed: September 29, 2014
    Publication date: August 18, 2016
    Inventors: Xiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI, Mark MULVIHILL
  • Antibacterial piperdine derivatives
    Patent number: 8399489
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: March 19, 2013
    Assignee: Astrazeneca AB
    Inventors: Gregory Basarab, Brian Dangel, Paul Robert Fleming, Michael Barry Gravestock, Oluyinka Green, Sheila Irene Hauck, Pamela Hill, Kenneth Gregory Hull, George Mullen, Haihong Ni, Brian Sherer, Fei Zhou
  • ANTIBACTERIAL PIPERDINE DERIVATIVES
    Publication number: 20100179150
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Application
    Filed: February 16, 2006
    Publication date: July 15, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Gregory Basarab, Brian Dangel, Paul Robert Fleming, Michael Barry Gravestock, Oluyinka Green, Sheila Irene Hauck, Pamela Hill, Kenneth Gregory Hull, George Mullen, Brian Sherer, Fei Zhou, Haihong Ni
  • Pyrrol derivatives with antibacterial activity
    Patent number: 7709503
    Abstract: Compounds of Formula (1) and their pharmaceutically acceptable salts are described: Formula (1) Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: May 4, 2010
    Assignee: AstraZeneca AB
    Inventors: Oluyinka Morenike Green, Kenneth Gregory Hull, Haihong Ni, Sheila Irene Hauck, George Byron Mullen, Alexander Louis Breeze, Neil James Hales, David Timms